No ratings

Good Tuesday afternoon folks. Before we even get a chance to forget, look for a new trading idea in your inbox tomorrow (Wednesday) morning, right around the open. We mentioned in Monday afternoon's newsletter we were finalizing some thoughts on a new Featured Stock. We wrapped up that review today, and will have it in your hands early tomorrow. We're excited about it, particularly in light of the news the company shared this morning.

We can't tell you any more about it right now, other than to let you know it's a junior gold mining stock, and now's the right time to be looking at gold stocks.

See, we still contend gold is on the verge of a major bullish reversal, which is even better for large gold miners, and better still for small gold miners. You can see on the chart below how the VanEck Vectors Gold Miners ETF (GDX) outperformed the SPDR Gold Trust ETF (GLD) when gold took a turn for the better in January. The VanEck Vectors Junior Gold Miners ETF (GDXJ) decidedly outpaced its large-cap counterpart.

No ratings

Good Monday afternoon everybody. How was your weekend? Or, maybe I should be asking how your Monday was, particularly if you made the RXi Pharmaceutical (RXII) trade we suggested in Friday's edition. It didn't take shape the way we were thinking/hoping it would, but it still did quite well today. Hopefully you got in and out, even if day-trading isn't your thing.

The specifics: RXII opened at $1.71 on Monday, and ended up going as high as $2.93 before all was said and done. It was reeled in shortly after that early morning peak, but even if you didn't get out at the high, any exit above $2.05 would have translated into a 20% gain....and that's the low end of the potential upside you could have enjoyed. Odds are good most of you were able to get out at a better price than that.

With that being said, we do want to let you know that members of the Under the Radar Movers service did a heck of a lot better. They made an exit at $2.05 (though some did even better), and with an entry price of $1.26 on November 17th, that translates into a gain of 62%. Not bad for three days work.

No ratings

Howdy folks. How was your Friday? Obviously it wasn't a great one for the market, but there are several reasons why other than the market is destined to move lower. That's not to say it won't move lower from here - it might. We're just saying don't jump to conclusions based on today's lull.

First though not foremost, today was an option expiration day. All those puts and calls require selling or exercising, and that can put pressure on a market.... bullish and bearish. Today's net effect looks like it was bearish, but come Monday, any such pressure will no longer be a factor.

Another modest possibility is the fact that with next week being a holiday week and trading effectively condensed to the first three trading days of the week, some people have every intention of taking the whole week off. Rather than stick with marginal positions for a whole week they're not even watching the market, they shed them.

No ratings

Does this rally make any sense? Not really. But, as they say, don't fight the tape. On the other hand, we all know too well that the trend is your friend... right up until the point where it isn't. Once the trend turns its back on you, it can become quite the enemy.

The trick? Trends try to make sure they can fool as many people as possible.

I only bring it up right now to provide the context for a discussion of this market. On the surface things look great, with the S&P 500 as well as the NASDAQ Composite both within easy striking distance of record highs. I just can't help but wonder if this strength is the market's way of luring everyone one, only so it can drop the boom on them at the exact worst time.

No ratings

Happy hump-day, folks, but no - the market didn't get over its key hump. It didn't even really try. Ugh.

We'll look at what happened and what it means in a moment, as we always do. We want to start with the most important news first though, which is this morning's press release from Vitality Biopharma (VBIO).

Just to get everybody up to speed in case you've not been able to keep up, here's the crash course on Vitality Biopharma.